Skip to main content

Towards faster and more economical drug development




Press & Communications Section Head
Tel.+34 93 40 37255

La Vanguardia has devoted an article to the Senén Vilaró Prize for the best innovative company, which has recently been awarded to Nostrum Biodiscovery (NBD). This prize acknowledges the capacity of the technology developed by this company to allow pharmaceutical companies to speed up drug discovery and reduce the costs involved.

NBD was founded in 2016 as a spin-off from the Institute for Research in Biomedicine (IRB Barcelona) and the Barcelona Supercomputing Center (BSC-CNS), with the objective to support the discovery and launch of new drugs and biotech molecules. Modesto Orozco, head of Molecullar Modelling and Bioinformatics lab and holder of an ERC Advanced Grant at IRB Barcelona, is one of the founders of this company.

Link to: La Vanguardia



0025dfv9_1.pdf (261.57 KB)

About IRB Barcelona

The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).